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2.1. Primary (genuine) and secondary (associated with stress, sepsis, stroke, pulmonary
and liver diseases, burn, trauma) Peptic Ulcer Diseases (PUD)
The criteria of diagnosis and treatment of peptic ulcer disease (PUD) have been changed
significantly in the past 40–50 years. At the beginning of this period, peptic ulcer disease was
only diagnosed by X-ray examination. Currently, gastrofiberoscopy has also become a
common practice in medical diagnosis.
Clinically, the PUD was divided into two groups: “primary” and “secondary”. The diseases
in the “secondary group” associated with a chronic liver, lung, brain damage or burn; however,
no obvious reasons for the PUD could be provided as the etiological factor and these forms of
the diseases were named as “genuine diseases.”
The presence of two main factors was emphasized in the development of gastroduodenal
ulceration: the hyperacidity and hypoxemic damage of gastroduodenal mucosa.
There was a significant contradiction between these mentioned factors, namely the gastric
hyperacidity associated with the increased gastric mucosal blood flow (GMBF) and ulcer
development, and it was practically impossible to understand the development of gastroduo‐
denal mucosal damage based on the increased gastroduodenal mucosal blood flow (Bowen
and Fairchild., 1984).
2.2. Medical treatment with anticholinergic agents in patients with gastric and duodenal
ulcers
Our scientific attention focused on the medical treatment of patients with peptic ulcer diseases
from 1960 onwards.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Our original aim was to create a complete scientific methodology for the evaluation of
efficiencies of different drugs (previously, parasympatholytic agents, antacids) in the field of
gastroenterology. We have to emphasize that during 1960–1970, no clinical pharmacology
existed.
We wanted to introduce into the conventional human clinical pharmacological approaches
using that we were established in our group at Debrecen, Hungary, in the field of gastroen‐
terology (in the period of 1962–1970).
Our interest focused on changes of gastric secretory responses in patients with duodenal ulcer
(DU) during chronic atropine treatment. In the earlier days, only atropine and scopolamine
were used for treating DU patients in whom we studied the presence of DU using X-ray
examination (fiberoptic endoscopy did not exist earlier).
We studied (at present) the changes of gastric acid secretory responses in patients with
duodenal ulcer before and after a classical medical treatment. We measured the gastric basal
acid output (BAO) and secretory responses to superluminal (but submaximal) dose of
histamine.
We were surprised to find that the patients with DU were cured by a chronic (2–4 weeks)
treatment  with  atropine.  However,  the  gastric  secretory  responses  in  patients  were  not




A chronic atropine treatment
A B A B
Volume of gastric juice (mL/h) 180±32 175±37 178±44 181±28
H+ output (mEq/h) 0.97±0.02 1.49±0.2 0.8±0.02 1.61±0.11
Table 1. Gastric secretory responses before and after (3 × 0.3 mg orally given for 2–4 weeks) a chronic atropine
treatment without and with histamine (A and B, respectively) (0.5 mg subcutaneously injected). The results were
expressed as means ± SEM in ten patients. P-values between the identical parameters before and after chronic atropine
treatments are not significant. [Mózsik et al., 1965c; 1966b (with kind permission).]
These results showed that duodenal protection could be obtained by independent effects on
acid secretion: a phenomenon that defied the earlier well-established view, “no acid, no ulcer”
originally pioneered by Lester Dragstedt in 1943 (Gustafson and Welling, 2010).
Following these observations, the acute inhibitory effect of atropine was tested on the gastric
acid secretion before and after a chronic atropine treatment. Here, we observed that the extent
of acute inhibitory effect of atropine on patients’ acid secretion decreased significantly after a
chronic treatment (Mózsik et al., 1965c; Mózsik and Jávor 1966b; Mózsik et al., 2011).




A chronic atropine treatment
A B A B
Volume of gastric juice (mL/h) 125±10 137±10 189±8 109±10
H+ output (mEq/h) 0.25±0.08 0.4±0.1 0.49±0.08 0.68±0.09
Table 2. Changes in the gastric secretory responses before and after (3×0.3 mg orally given for 2–weeks) a chronic
atropine treatment without and with histamine (A and B, respectively) (0.5 mg subcutaneously injected)
administration in eight patients. The results were expressed as means ± SEM. P-values between the identical














Figure 1. Decreased inhibitory effect of atropine (1 mg sc.) before (A) and after (B) chronic atropine treatment in pa‐
tients with peptic ulcer disease (n = 8; means ± SEM).The results are expressed in percentage of their control. [Mózsik,
Szabó, Czimmer: Curr. Pharm. Des. 17: 1556–1572, 2011 (with kind permission).]
2.3. Clinical Pharmacology of anticholinergic agents in patients with peptic ulcer disease
(measurements of anticholinergic agents in the sera, urine in patients with duodenal ulcer)
It was hard to understand our previously demonstrated results obtained with application of
atropine treatment in patients with duodenal ulcer because these results contradict the
international experts’ opinions. We assumed that:
1. The atropine will not absorb from the gastrointestinal tract owing to some reasons (e.g.,
some pharmaceutical industrial problem(s) appeared during the drug pharmaceutical
production );
2. Even if the atropine absorbs well, some other unknown pharmacological event (such as
tolerance) will appear during a chronic (classical) atropine treatment.
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To evaluate these questions, we have to establish the real basis of clinical pharmacology.
Therefore, we have to provide a good and scientific possibility to bring about different answers
for our questions.
In the first step, the concentration of anticholinergic agents was measured by sera and urine
bioassay (using isolated guinea-pig ileum for biological titration of parasympatholytic drugs
in Magnus vessel) of patients. The absorption, metabolism and urinary excretion of parasym‐
patholytics were studied after chronically applied parasympatholytic treatments (Győrffy et
al., 1964; Jávor et al., 1965; 1967; Mozsik, 1969a; Mózsik et al., 1965 a, b; 1967d; Mozsik and
Jávor, 1966 a, b, c; 1968a).
The atropine absorbed well from the gastrointestinal tract (during 4–5 hours), and it was
proved by titration of atropine in the sera and urine of patients. These observations were
carried out in the same patients when the same doses of atropine were given orally or
subcutaneously injected. It was clear that the absorbed quantities of atropine were the same
(given in the same doses), indicating that the oral/parenteral ration of atropine absorption is
equal to 1.0. Furthermore, when we carried out these observations, we found the same results
(with respect to the absorption and excretion of atropine) in the treated patients.
Since we had classical clinical pharmacological methods (e.g., detection of small doses of
atropine in the serum and urine of treated patients), we were able to exclude any changes of
absorption in gastrointestinal tract, metabolism and urinary excretion of atropine as a conse‐
quence of the effects of chronic atropine treatment (Mózsik et al., 1966 a, b, c; 1968; 1969 a, b,
c, d, e, f; Mózsik, 1969a).
Later, we observed the development of tolerance along with the development of “pharmaco‐
logical denervation supersensitivity” (e.g., the efficiencies of drugs used in the treatment of
patients decreased significantly). These phenomena exist together (Mózsik et al., 1967a; Mózsik
and Jávor, 1968 a, b) in the background of unchanged gastric acid secretion during a chronic
atropine treatment in DU patients. It was also interesting to note the development of tolerance
to atropine and the disappearance of pharmacological denervation phenomena in 6–10 days
after cessation of atropine treatment (Mózsik et al., 1965b; Mózsik and Jávor, 1968b; 1969;
Mózsik, 1969a). The development of tolerance to atropine does not represent a specific
phenomenon related to atropine (during a chronic atropine treatment) because the develop‐
ment of tolerance was found with other parasympatholytics, which were not used in the
medical treatment (Mózsik and Jávor, 1969).
The results of the clinical pharmacological studies proved the following main points:
1. No change was obtained in the gastric acid secretion during a chronic anticholinergic
treatment;
2. The gastroduodenal ulceration healed during this time period;
3. The results of the clinical pharmacology could not provide an obvious explanation of how
the gastroduodenal ulceration was healed without any changes in gastric secretory
responses (Mózsik et al., 1965b; 1967a; Mózsik and Jávor, 1966b; 1968 a, b; 1969; Mózsik,
1969a).
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This clinical pharmacological methodology was applied in the medical evaluation of different
anticholinergic agents (drugs) before their clinical applications.
Recently, the pharmacological basic research offered a possibility to introduce new anticholi‐
nergic agents into the medical practice. The experts working in the field of experimental
pharmacology showed that the actions of these anticholinergic agents can be enhanced on the
autonomic nervous system by the changes in their chemical structures (perhaps by the
production of quaternary ammonium compounds instead of only tertiary quaternary ammo‐
nium compounds) (Gyermek, 1951; 1953; Gyermek and Nádor, 1952; 1953 a, b; György et al.,
1961).
The Gastropin® is one of the most representative quaternary ammonium compounds, which
was introduced into the medical treatment in the 1960s. We were clearly able to prove that the
Gastropin® does not absorb from the gastrointestinal tract. We were not able to detect any drug
levels in the serum and urine of patients when the patients were orally given 1000 pills;
however, these parameters were well detectable after it was injected in the same patients.
The established clinical pharmacological methods were widely used in the evaluation of
different anticholinergic agents (Mózsik, 1969a).
Many clinical pharmacological studies (from human phase I to III) were carried out by our
work team who were working on different drugs [(tertiary amine, oxyphen cylamine),
muscarinic receptor blocking (gastrozepin), histamine2 receptor blocking (first to fourth
generation), proton pump inhibitors and other components] for patients with peptic ulcer
(Mózsik et al., 1965b; Mózsik, 1969a; Jávor et al., 1967; Garamszegi et al., 1997; Nagy et al., 1997;
Tárnok et al., 1979, 1997).
2.4. Comparative clinical pharmacology of anticholinergic drugs
Different clinical pharmacological studies were carried out in patients with peptic ulcer to
compare the detectable concentrations in the sera, excretion in the urine and bile, inhibitory
actions on the salivary secretion, gastric acid secretion, necessary dose rate to decrease
glandular secretion and gastric motility, detectability of drug to proteins and the excretion
time. The results are summarized in Table 3.
Atropine Novatropine Isopropamide
Oral – parenteral dose rate 1 : 1 6-8 : 1 4-6 : 1
Detectable in serum + + -
Detectable in urine + + +
Detectable in saliva - - +
Detectable in bile - - +
Necessary dose rate to decreased glandular
secretion and the gastric motility 1 : 2 1 : 2 1 : 2




Ihibitory effect on salivary secretition + ++ -
Inhibitory effect of gastric secretion + ++ ++
Inhibitory effect of gastric
emtying in decreasing dose
of glandular secretion
- - +
Duration of inhibitory effect on the salivary
secretion 3-4 hours 6-8 hours 10-15 hours
Excretion in urine up 3-4 hours 6-8 hours 10-15 hours
detectable protein binding
of the drug in serum
Table 3. Comparative demonstration of the clinical pharmacological properties of parasympatholytics. [Mózsik, Vizi,
Jávor, Recent Advances in Gastroenterology. The 3rd World Congress of Gastroenterology, Tokyo, 1967, 681–683 (with
kind permission).]
Figure 2. The schematic presentation of the measured serum levels of different parasympatholytic drugs in peptic ul‐
cer patients. The ordinate shows the level of parasympatholytic drugs (toxic, effective and ineffective); the abscisse
demonstrates the time after administration of these drugs. a: atropine; N: Novatropine; I: isopropamide. [Mózsik, Vizi,
Jávor: Recent Advances in Gastroenterology. The 3rd World Congress of Gastroenterology, Tokyo, 1967, 681–683 (with
kind permission).]
Membrane-bound Atp-dependent Energy Systems and the Gastrointestinal Mucosal Damage and Protection12
2.5. Clinical evidence of the existence of gastrointestinal protection differs from the decrease
of gastric acid secretion (Gastric cytoprotection)
The results of our observation of chronic atropine treatment in DU patients were given in detail
previously.
In 1978, we found that the GI anti-ulcer effects of atropine, cimetidine and carbenoxolone were
superior to placebo in a multiclinical, randomized, prospective and comparative study in DU
patients. However, no significant difference was obtained in the beneficial effects of atropine
versus cimetidine versus carbenoxolone (Tárnok et al., 1979). Since carbenoxolone has no
inhibitory action on the gastric acid secretion in DU patients, the ulcer-healing effects (due to
stimulation of mucus) could be considered independent of any effects on gastric acid secretion.
Thus, these clinical observations during 1960–1970 were performed before the classical concept
of “gastric cytoprotection” was formulated and published by André Robert (Robert et al., 1979).
Figure 3. A prospective multiclinical study comparing the effects of placebo, carbenoxolone, atropine and cimetidine in
patients with duodenal ulcer (4 weeks’ study). [Tárnok et al., Drugs Exp. Clin. Res. 5: 157–166, 1979 and Mózsik, Szabó,
Czimmer, Curr. Pharm. Des. 17: 1556–1572, 2011 (with kind permission).]
Our clinical pharmacological studies (1965) (Mózsik et al., 1965b; 1967 a, b, c, d; Mózsik and
Jávor, 1968 a, b; Mózsik, 1969a; Tárnok et al., 1979) as well as randomized, prospective,
multiclinical and comparative studies (1978) are clear even now in retrospect that we had been
observing acid-independent gastroduodenal protection with atropine and other drugs before
André Robert had defined the existence of “gastric cytoprotection” (Mózsik, 2010; Mózsik et
al., 2011).
During 1965–1970, the existence of “gastric cytoprotection” was not reported; conversely, the
clinical importance of gastric acid secretion had only been emphasized. Chaudhury and
Jacobson (1978) were the first to indicate that the gastric mucosal damage could be prevented
without inhibition of gastric secretion.
The existence of “gastric cytoprotection” has been widely accepted after the work of Robert et
al. (1979) in animal experiments. The clinical applicability of gastric cytoprotection was later
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accepted for patients with gastroduodenal ulcer (with the exception of our previously carried
out observations in DU patients).
2.6. Randomized, multiclinical, prospective and multicentric study of treatment of chronic
gastric ulcer patients with vitamin A
Later, we demonstrated in multiclinical, multicentric, prospective and randomized study the
ulcer-healing effect of vitamin A (as scavenger component) in patients with gastric ulcer (Patty
et al., 1982; 1983). However, no gastric acid inhibitory action of the vitamin A exists in humans
(Jávor et al., 1983 a, b; Mózsik et al., 1986; 2001; 2005; 2007; Rumi et al., 2001 a, b).
Figure 4. Evaluation of the different treatments of efficiency of vitamin A in patients with chronic gastric ulcer (4
weeks of study). The endoscopic and laboratory parameters were carried out at the beginning and during 2 and 4
weeks after the beginning of the treatment; meanwhile, the changes of complaints and consumption of antacids in pa‐
tients were registered every day and these values were summarized with the similar points in this clinical study. [Patty
et al., Lancet II, 872, 1982; Int. J. Tiss. React. 5: 301–307, 1983 (with kind permission).]
Fifty-six patients with chronic gastric ulcer were examined for this multiclinical, multicentric,
randomized and prospective study (Patty et al., 1982; 1983).
The patients were divided into three groups: group A (16 patients) received only antacids;
group B (18 patients) were treated with antacids plus vitamin A (3 × 50,000 IU orally) and group
C (22 patients) received antacids, vitamin A (3 × 50,000 IU orally) and cyproheptadine
(Peritol®).The observations were carried out in 4 weeks’ time.
Endoscopic measurements, and clinical and laboratory parameters were carried out at the
beginning and at the end (2nd and 4th week) of the treatment of these patients (Figure 4).
The parameters in Figure 4 help us to evaluate the different objective (planimetric measure‐
ment of ulcer sizes, presence or absence of gastric ulcer – at the beginning and end of different
treatments – and states of ulcer) and subjective (changes in complaints of patients and
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consumption of antacids) events of the process of ulcer healing (including the possible roles
of drug actions). The obtained results are summarized in Figures 5–8.
The dynamism of the ulcer healing can be scientifically studied by the changes of ulcer sizes
at 2 and 4 weeks after beginning the treatment (Figure 8). It was surprising to note that the
healing rate differed significantly at 2 weeks; however, this value was the same at 4 weeks.
Figure 5. Changes in the antacid consumption in the different groups of patients with chronic gastric ulcer. [Patty et
al., Lancet II, 872, 1982; Int. J. Tiss. React. 5: 301–307, 1983 (with kind permission).]
Figure 6. Changes of gastric ulcer indices in patients treated with antacids (A); antacids plus vitamin A (B) and ant‐
acids, vitamin A and Peritol® (C) during 4 weeks of treatment. [Patty et al., Lancet II, 872, 1982; Patty et al., Int. J. Tiss.
React. 5: 301–307, 1983 (with kind permission).]
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Figure 7. A. Changes in number (and percentage) of completely healed gastric ulcers in patients treated with antacids
(A); antacid plus vitamin A (B) and antacid, vitamin A and Peritol® (C) during 4 weeks of treatment (with kind permis‐
sion). B. Reduction of original planimetric size of gastric ulcers in patients treated with antacids (A); antacids plus vita‐
min A (B) and antacids, vitamin A plus Peritol® (C) before and after 4 weeks of treatment. [Patty et al., Lancet II, 872,
1982; Patty et al., Int. J. Tiss. React. 5: 301–307, 1983 (with kind permission).]
2.7. Comparative clinical pharmacology of “cytoprotective” and “anti-secretory” drugs
(multiclinical, randomized, prospective and multicentric studies) in patients with chronic
gastric and duodenal ulcers
Our work team participated in the clinical pharmacological studies of peptic ulcer patients
(including different international studies as well as ours). After our previously performed
studies, our attention focused on the results of clinical pharmacological studies with “cyto‐
protective” and “anti-secretory” drugs in patients with chronic gastric and duodenal ulcers.
In this subchapter, we summarized the results of clinical pharmacological studies of 441
chronic gastric and duodenal ulcers. The patients treated with nonsteroidal, anti-inflammatory
drugs, steroids, antihypertensive drugs (e.g., Reserpine) and those who underwent some
stress, burns or trauma were excluded from this comparative study. These patients were
divided into different groups and were treated with different drugs: placebo (calcium
carbonicum, magnesium trisilicate and sodium bicarbonate in equal portion), atropine (1.0
mg/os), cimetidine (1000 mg/day orally), ranitidine (300 mg/day orally), famotidine (80
mg/day orally), pirenzepine (150 mg/day orally), sucralfate (1000 mg/day orally), vitamin A
(3 × 50,000 IU/day orally) alone or in combination with cyproheptadinum chloratum (3 × 4 mg/
Membrane-bound Atp-dependent Energy Systems and the Gastrointestinal Mucosal Damage and Protection16
day orally), DE-NOL (3 × 5 mL/day orally) and Tisacid® (Al–Mg–antacidum 3 × 1 g/day orally).
The antacids in composition mentioned above were applied with the so-called active com‐
pounds. Twenty patients were allocated into each group. The treatments were carried out for
4 or 6 weeks. (These results are reused with the permission of Wiley publisher.)
Endoscopy (estimation of ulcer size), laboratory measurements (blood count, urine, kidney
and liver functions), pH status, medical examinations, summed pain score (expressed in
percentage of original values) and antacid consumption were evaluated at the beginning,
during 2nd, 4th and 6th week (if the treatment extends) and after the treatment.
The aims of this study are as follows:
1. To compare the efficiencies of ulcer treatments by cytoprotective (Tisacid®, sucralfate, DE-
NOL and vitamin A) and anti-secretory (atropine, pirenzepine, cimetidine, ranitidine,
famotidine) drugs in a short-term study (4–6 weeks);
2. To evaluate the dynamism of ulcer healing in unhealed gastric and duodenal patients;
3. To evaluate the summed pain score and antacid consumption in GU and DU patients;
4. To compare the different results (ulcer healing, laboratory parameters, summed pain score
and antacids) obtained in healed and unhealed GU and DU patients.
Figure 8. Dynamism of ulcer-healing effect of vitamin A in patients with chronic gastric ulcer, indicating the changes
of ulcer size in unhealed patients (in 4 weeks of treatment). [Patty et al., Lancet II, 872, 1982; Patty et al., Int. J. Tiss.
React. 5: 301–307, 1983 (with kind permission).]
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Treatment Number of Patients Number of UnhealedPatients (%) P-value
Antacid 40 30(75) -
Al-Mg-hydroxy- Carbonate
(Tisacid® ) 15 10(66.7) NS
Vitamin A 18 11(61.1) <0.05
Vitamin A and cyproheptadine 22 14(63.9) <0.05
DE-NOL 16 5 ( 31.2) <0.01
Sucralfate 19 14(73.7) NS
Gastrozepine 16 9 ( 56.2) < 0.0.5
Cimetidine 30 8 ( 26.7) < 0.01
Table 4. Changes in the incidence of gastric ulcer (GU) healing during 4 weeks of treatment with different groups of
patients compared with antacid. The numbers in parentheses are calculated in percentage. NS: not significant [Mózsik
et al., J. Gastroenterol. Hepatol 9: S88–S92, 1994 (with kind permission).]
Figure 9. Changes in ulcer-healing rate during the different therapies in patients with chronic gastric ulcer (4 weeks).
The results are expressed as means; n indicates the number of patients. P-values between the groups treated with ant‐
acids (placebo) and different groups. +: P < 00.5; ++: P < 00.1; NS: not significant. [Mózsik et al., J. Gastroenterol. Hepa‐
tol 9: S88–S92, 1994 (with kind permission).]
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Figure 10. Changes in the ulcer size of patients with incompletely healed gastric ulcer during 4 weeks of treatment.
The ulcer size was perceived at the beginning (first bar), 2 weeks (middle bar) and 4 weeks (right bar) of the treatment
(n, the number of incompletely healed patients). P-values are based on the ulcer size at the beginning and at 2 and 4
weeks; *: P < 0.0.5; **: P < 0.01; ***: P < 0.00.1; NS: not significant. [Mózsik et al., J. Gastroenterol. Hepatol 9: S88–S92,




Antacid 22 14 (63.6)
Al-Mghydroxy- carbonate (Tisacid®) 39 13 (33.3) < 0.0.5
Atropine and Cyproheptadine 22 5 (22.7) < 0.0.1
Atropine and Cimetidine 25 9 (36) < 0.0.5
Cimetidine 25 9 (36) < 0.0.5
Ranitidine 25 9 (36) < 0.0.5
Famotidine 33 9 (27.3) < 0.0.1
Carbenoxolone 19 8 (42.1) < 0.0.5
Sucralfate 31 15 (45.4) < 0.0.5
Gastroozepine 24 10 (41.7) < 0.0.5
Table 5. Changes in the incidence of duodenal ulcer healing during 4 weeks of treatment in different groups of
patients compared with antacid. The numbers in parentheses are calculated in percentage. [Mózsik et al., J.
Gastroenterol. Hepatol 9: S88–S92, 1994 (with kind permission).]
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Figure 11. Changes in ulcer-healing rate in chronic duodenal ulcer patients treated with different drugs. P-values are
between antacid (placebo) and treated groups at 4 and 6 weeks. *: P < 0.05; ***: P < 0.001; NS: not significant. [Mózsik et
al., J. Gastroenterol. Hepatol 9: S88–S92, 1994 (with kind permission).]
Figure 12. Changes in ulcer size in patients with incompletely healed duodenal ulcer after 4 weeks of treatment. Ulcer
size before treatment = 1. [Mózsik et al., J. Gastroenterol. Hepatol 9: S88–S92, 1994 (with kind permission).]
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2.8. General conclusion(s) of clinical pharmacological studies in patients with peptic ulcer
Returning the results of our earlier clinical pharmacological studies in patients with duodenal
ulcer (see before), our final conclusion was that we have no any correct knowledge on the
principle biochemical cellular and extracellular changes (mechanisms) are present in the
keeping the normal homeostasis of the GI mucosa, and in time of development of GI mucosal
damage and protection neither in animal experiments nor in humans (patients).
In addition to these, the discovery of “gastric cytoprotection” represented a new challenge to
us in answer to the scientific problem mentioned above.
The results of these observations helped us to start a new scale of examinations in the field of
peptic ulcer disease. We wanted to start with biochemical examinations in this field, but,
unfortunately, nobody worked on it. Consequently, we have to learn the principal points of
the general biochemical research to introduce it into the field of peptic ulcer research.
We have to emphasize that scientific problems and their knowledge have been changing over
the past few decades, and many new scientific results are published.
Four well-known scientists were awarded the Nobel Prize [Jens Christian Skou (Department
of Physiology, Aarhus University, Denmark) in chemistry, 1997; Earl W. Sutherland (Depart‐
ment of Physiology, Vanderbilt University, Nashville, TN, USA) in physiology (medicine),
1971; and Barry James Marshall and J. Robin Warren (Royal Perth Hospital, Australia) in
physiology (medicine), 2005]. Their results inspired es to ttudy these fields in our peptic ulcer
research in animals and humans.
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